Compare DAC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | FTRE |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2006 | N/A |
| Metric | DAC | FTRE |
|---|---|---|
| Price | $101.00 | $17.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $105.00 | $15.56 |
| AVG Volume (30 Days) | 70.0K | ★ 1.3M |
| Earning Date | 02-09-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 25.05 | N/A |
| Revenue | $1,034,370,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | N/A | $0.07 |
| P/E Ratio | $4.02 | ★ N/A |
| Revenue Growth | ★ 2.90 | 1.88 |
| 52 Week Low | $65.40 | $3.97 |
| 52 Week High | $102.20 | $19.00 |
| Indicator | DAC | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 66.00 | 57.07 |
| Support Level | $98.41 | $15.37 |
| Resistance Level | $101.72 | $17.24 |
| Average True Range (ATR) | 2.04 | 1.20 |
| MACD | 0.30 | -0.23 |
| Stochastic Oscillator | 90.52 | 61.21 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.